Handelsbanken Fonder AB Sells 72,000 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

Handelsbanken Fonder AB cut its stake in TransMedics Group, Inc. (NASDAQ:TMDX) by 87.9% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 9,900 shares of the company’s stock after selling 72,000 shares during the period. Handelsbanken Fonder AB’s holdings in TransMedics Group were worth $666,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in TMDX. Braidwell LP bought a new stake in TransMedics Group in the fourth quarter valued at approximately $57,493,000. Norges Bank acquired a new position in TransMedics Group in the fourth quarter valued at approximately $22,861,000. Mackenzie Financial Corp lifted its stake in TransMedics Group by 73.0% in the fourth quarter. Mackenzie Financial Corp now owns 828,147 shares of the company’s stock valued at $51,635,000 after buying an additional 349,403 shares during the period. Dimensional Fund Advisors LP lifted its stake in TransMedics Group by 1,565.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 269,825 shares of the company’s stock valued at $16,820,000 after buying an additional 253,624 shares during the period. Finally, Emerald Advisers LLC lifted its stake in TransMedics Group by 146.3% in the fourth quarter. Emerald Advisers LLC now owns 371,711 shares of the company’s stock valued at $23,176,000 after buying an additional 220,804 shares during the period. 99.67% of the stock is currently owned by institutional investors.

Insider Activity at TransMedics Group

In related news, insider Anil P. Ranganath sold 686 shares of TransMedics Group stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $139.80, for a total value of $95,902.80. Following the completion of the sale, the insider now owns 13,955 shares of the company’s stock, valued at approximately $1,950,909. This trade represents a 4.69% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Edward M. Basile sold 6,000 shares of TransMedics Group stock in a transaction dated Friday, May 9th. The stock was sold at an average price of $115.63, for a total value of $693,780.00. Following the completion of the sale, the director now directly owns 732 shares of the company’s stock, valued at approximately $84,641.16. This trade represents a 89.13% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 12,418 shares of company stock valued at $1,512,613. 7.00% of the stock is owned by insiders.

Analysts Set New Price Targets

Several equities analysts have issued reports on TMDX shares. Needham & Company LLC reissued a “hold” rating on shares of TransMedics Group in a research note on Tuesday, June 3rd. Piper Sandler reissued an “overweight” rating and issued a $145.00 price target (up from $125.00) on shares of TransMedics Group in a research note on Wednesday, June 4th. Canaccord Genuity Group reissued a “buy” rating and issued a $104.00 price target on shares of TransMedics Group in a research note on Tuesday, March 11th. Finally, Oppenheimer boosted their price target on TransMedics Group from $125.00 to $130.00 and gave the company an “outperform” rating in a research note on Friday, May 9th. Three equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, TransMedics Group currently has a consensus rating of “Moderate Buy” and a consensus target price of $125.11.

TransMedics Group Price Performance

Shares of NASDAQ:TMDX opened at $142.88 on Monday. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42. TransMedics Group, Inc. has a twelve month low of $55.00 and a twelve month high of $177.37. The stock’s 50 day moving average is $108.75 and its 200-day moving average is $82.38. The firm has a market capitalization of $4.83 billion, a price-to-earnings ratio of 152.00 and a beta of 2.10.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings results on Thursday, May 8th. The company reported $0.70 EPS for the quarter, beating analysts’ consensus estimates of $0.29 by $0.41. The business had revenue of $143.54 million during the quarter, compared to analyst estimates of $123.39 million. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. TransMedics Group’s quarterly revenue was up 48.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.35 EPS. Sell-side analysts forecast that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.